Company intelligence / Profile preview
Sintetica
Mendrisio, Ticino, Switzerlandsintetica.com ↗
- Ownership
- Private
- Employees
- ~300
- Development stage
- Other
01
Overview
Sintetica has received FDA approval for its Couvet Plant in 2023, allowing direct sales of drugs on the American market. The company has also developed products like Ampres® (Chloroprocaine-based local anesthetic) and Takipril® (hyperbaric Prilocaine for spinal administration).
- Therapeutic areas
- OtherNeurology
- Modalities
- Injectable solutionsliquid sterile formulations
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Sintetica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sintetica.